Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab

This secondary analysis of the phase 1 CA209-003 clinical trial assesses the 5-year survival and other related factors among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer receiving nivolumab.

Read the full article here

Related Articles